Neoplasms

Digestive System Diseases

All Conditions

Symptoms and General Pathology

Rectal Neoplasms

Hypoxia

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Signs and Symptoms, Respiratory

Biopsy, Blood sample, F-MISO PET, pCT, functional MRI, Pimonidazole

Biopsy, Blood sample, F-MISO PET, pCT, functional MRI

Pimonidazole

F-MISO PET

Functional MRI

Biopsy

Blood sample

Tim Maughan

A low level of oxygen in cancer cells makes them less likely to respond to chemotherapy and radiotherapy treatments. There is interest in using new drugs that improve the level of oxygen in tumours. Another approach would be to increase the radiotherapy dose to tumours with low oxygen levels.

Before we can do this for patients with rectal cancer, we need to develop a reliable way of identifying areas of low oxygen within the rectal tumour. This will make us able to tell which patients may be suitable for such a change in their treatment.

Traditionally, the level of oxygen in tumours is measured by inserting a needle into the tumour and measuring it directly. This is not possible in rectal cancer. This study has been designed to identify the best alternative method. We would like to do a blood test, take samples of cancer tissue and some detailed scans (18F-fluoromisonidazole (F-MISO) positron emission tomography, perfusion computed tomography, functional magnetic resonance imaging). The results of these tests will be compared to decide which gives us the most comprehensive and reliable information.

Patients in Group A go straight to surgery. By looking for markers of low oxygen levels on the tumour that has been removed, we will be able to find out which of the study tests performed before the tumour was removed is the best. By repeating the scans we will be able to see how reliable they are and how much they change on a day to day basis. We think that tumours that still have low levels of oxygen after 8 to 10 doses of radiotherapy are the least likely to respond to treatment.

Group B will have scans before radiotherapy treatment and after 8 to 10 doses of radiotherapy to see if we can identify the patients that have persistent low levels of oxygen.

RHYTHM-I: Investigating Hypoxia in Rectal Tumours

RHYTHM-I: Modulation of Radiotherapy According to HYpoxia: Exploiting Changes in the Tumour Microenvironment to Improve Outcome in Rectal Cancer.

Blood samples will be taken at each imaging time point for investigational work to identify potential circulating hypoxia biomarkers.

Comparison of F-MISO PET hypoxic volumes with fractal analysis of pCT images.

Radiotherapy planning feasibility study to determine if it is feasible to change the radiotherapy dose distribution or total dose in response to functional imaging after 8-10 fractions of radiotherapy.

Validation of FMISO-PET as a measure of hypoxia in rectal cancer.

FMISO-PET derived hypoxic volumes will be compared to reconstructed volumes from the immunohistochemistry of PIMO, CAIX and HIF on whole mount histology of the resected tumour.

The spatial distribution of FMISO uptake on PET images will be compared with PIMO, CAIX and HIF immunohistochemistry distributions in the resected tumour.

Quantifying the percentage change in FMISO SUVmax and uptake volume between the two FMISO-PET scans after 8-10 fractions of CRT.

Group A: To assess if F-MISO PET defined hypoxia correlates with hypoxia metagene expression.

Group B: To assess if baseline measures of hypoxia and the presence of tumour hypoxia after 8-10 fractions of CRT correlate with radiological/pathological response.

Group A: Assess inter-individual variability in FMISO uptake and intra-individual reproducibility of FMISO-PET in rectal cancer.

Group B: Determine correlation of baseline and day 10-12 FMISO-PET SUVmax with radiological/pathological response, immunohistochemical and genetic markers of hypoxia and other factors affecting response to radiotherapy following CRT.

Group A: Assess inter-individual variability in pCT derived blood flow parameters and intra-individual reproducibility of pCT in rectal cancer. Assessment of the utility of pCT derived AIF in the processing of dynamic FMISO-PET scans.

Group B: Quantitative changes in pCT derived blood flow parameters after 8-10 fractions of CRT.

Group A: Comparison of changes in T1/T2\* MRI before and after supplemental oxygen breathing.

Group B: Changes in native T1/T2\* MRI from baseline and before and after supplemental oxygen breathing.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
RHYTHM-I: Investigating Hypoxia in Rectal Tumours	NCT02157246	Hypoxia in Rect...	Pimonidazole F-MISO PET pCT Functional MRI Biopsy Blood sample	18 Years -	University of Oxford
RHYTHM-I: Investigating Hypoxia in Rectal Tumours	NCT02157246	Hypoxia in Rect...	Pimonidazole F-MISO PET pCT Functional MRI Biopsy Blood sample	18 Years -	University of Oxford

Spots Global Cancer Trial Database for pct

Every month we try and update this database with for pct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for pct

Every month we try and update this database with for pct cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for pct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.